Role of immune checkpoint inhibitors in metastatic uveal melanoma: a single-center retrospective cohort study

References

• Khoja L, Atenafu E, Suciu S, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30(8):1370–1380.
   PubMed Web of Science ®Google Scholar
• National Organization for Rare Disorders. Rarediseases.org [Internet]. Ocular melanoma. 2018. https://rarediseases.org/rare-diseases/ocular-melanoma
   Google Scholar
• Rantala ES, Hernberg MM, Piperno-Neumann S, et al. Metastatic uveal melanoma: the final frontier. Prog Retin Eye Res. 2022;90:1–53.
   Web of Science ®Google Scholar
• Valasapalli S, Guddati AK. Nation-wide trends in incidence-based mortality of patients with ocular melanoma in USA: 2000 to 2018. Int J Gen Med. 2021;14:4171–4176.
   PubMed Web of Science ®Google Scholar
• Patel DR, Patel BC. Ocular melanoma. Treasure Island (FL): statPearls Publishing; 2022.
   Google Scholar
• Pane A, Hirst L. Ultraviolet light exposure as a risk factor for ocular melanoma in Queensland, Australia. Ophthalmic Epidemiol. 2000;7(3):159–167.
   PubMedGoogle Scholar
• American Society of Clinical Oncology. Cancer.net [Internet]. Eye Cancer. 2020. [cited 2022 Aug 6]. Available from: https://www.cancer.net/cancer-types/eye-cancer/view-all.
   Google Scholar
• Diener-West M, Earle JD, Fine SL, et al. The coms randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119(7):969–982.
   PubMedGoogle Scholar
• Rowcroft A, Loveday BPT, Thomson BNJ, et al. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB. 2020;22(4):497–505.
   PubMed Web of Science ®Google Scholar
• Dhamani AM, Shaikh IN, Advani S, et al. Redefining the treatment of metastatic uveal melanoma with immunotherapy – A case report. IJMIO. 2022;7(2):46–49.
   Google Scholar
• Bol K, Ellebaek E, Hoejberg L, et al. Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma. Cancers. 2019;11(10):1489.
   PubMed Web of Science ®Google Scholar
• Pelster M, Gruschkus S, Bassett R, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results From a Single-Arm phase II study. J Clin Oncol. 2021;39(6):599–607.
   PubMed Web of Science ®Google Scholar
• Piulats J, Espinosa E, de la Cruz Merino L, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39(6):586–598.
   PubMed Web of Science ®Google Scholar
• Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385(13):1196–1206.
   PubMed Web of Science ®Google Scholar
• Olivier T, Prasad V. Tebentafusp in first-line melanoma trials: an outperforming outlier. Transl Oncol. 2022;20:4–7.
   Web of Science ®Google Scholar
• Cerbone L, Van Ginderdeuren R, Van Den Oord J, et al. Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease. Oncol. 2014;86(3):185–189.
   Google Scholar
• Algazi A, Tsai K, Shoushtari A, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344–3353.
   PubMed Web of Science ®Google Scholar
• Zhao L, Xia W, Zhang Y, et al. Efficacy and safety of immune checkpoint blockades in the treatment of ocular melanoma: a systematic review and meta-analysis. Front Oncol. 2021;11:1–10.
   Web of Science ®Google Scholar
• Heppt MV, Amaral T, Kähler KC, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7(1):1–9.
   PubMed Web of Science ®Google Scholar
• Najjar YG, Navrazhina K, Ding F, et al. Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study. J Immunother Cancer. 2020;8(1):e000331.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.
   PubMed Web of Science ®Google Scholar
• Peterson C, Denlinger N, Yang Y. Recent advances and challenges in cancer immunotherapy. Cancers (Basel). 2022;14(16):3972.
   PubMed Web of Science ®Google Scholar
• Szeligo BM, Ivey AD, Boone BA. Poor response to checkpoint immunotherapy in uveal melanoma highlights the persistent need for innovative regional therapy approaches to manage liver metastases. Cancers (Basel). 2021;13(14):3426.
   PubMed Web of Science ®Google Scholar
• Komatsubara K, Carvajal R. Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies. Curr Oncol Rep. 2017;19(7):45.
   PubMed Web of Science ®Google Scholar
• Rietschel P, Panageas KS, Hanlon C, et al. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23(31):8076–8080.
   PubMed Web of Science ®Google Scholar
• Rossi E, Croce M, Reggiani F, et al. Uveal melanoma metastasis. Cancers (Basel). 2021;13(22):5684.
   PubMed Web of Science ®Google Scholar
• Blomen C, Kött J, Hartung T, et al. Combination of immune checkpoint inhibitors and liver-specific therapies in liver-metastatic uveal melanoma: can we thus overcome its high resistance? Cancers (Basel). 2021;13(24):6390.
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Mobuchon L, Houy A, et al. Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors. Nat Commun. 2018;9(1):1–6.
   PubMedGoogle Scholar
• Levey AO, Elsayed M, Lawson DH, et al. Predictors of overall and Progression-Free survival in patients with ocular melanoma metastatic to the liver undergoing Y90 radioembolization. Cardiovasc Intervent Radiol. 2020;43(2):254–263.
   PubMed Web of Science ®Google Scholar
• Tong TML, van der Kooij MK, Speetjens FM, et al. Combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase ib/randomized phase II trial. Trials. 2022;23(1):1–13.
   PubMed Web of Science ®Google Scholar